Fresh Tracks Therapeutics, Inc. (FRTX)の価格はいくらですか

Fresh Tracks Therapeutics, Inc. (FRTX)の価格は$0.94です

Fresh Tracks Therapeutics, Inc. (FRTX)の時価総額は何ですか

Fresh Tracks Therapeutics, Inc. (FRTX)の時価総額は$2.73Mです

Fresh Tracks Therapeutics, Inc. (FRTX) の利益

Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.

年	利益	変化
2026 (TTM)	$-5.89M	3.46%
2023	$-5.69M	-73.02%
2022	$-21.10M	-46.54%
2021	$-39.47M	88.75%
2020	$-20.91M	-12.41%
2019	$-23.88M	46.90%
2018	$-16.25M	25.42%
2017	$-12.96M	44.43%
2016	$-8.97M	-2.87%
2015	$-9.24M	-43.98%
2014	$-16.49M	-47.21%
2013	$-31.24M	36.42%
2012	$-22.90M	214.42%
2011	$-7.28M	-76.03%
2010	$-30.39M	6.40%
2009	$-28.56M	-22.56%
2008	$-36.88M	3.01%
2007	$-35.80M	56.49%
2006	$-22.88M	0.00%
2005	0.00	0.00%
2004	0.00	-100.00%
2003	$-26.59M	-25.80%
2002	$-35.83M	0.00%
2001	0.00	0.00%
2000	0.00	0.00%

年

利益

変化

2026 (TTM)

$-5.89M

3.46%

2023

$-5.69M

-73.02%

2022

$-21.10M

-46.54%

2021

$-39.47M

88.75%

2020

$-20.91M

-12.41%

2019

$-23.88M

46.90%

2018

$-16.25M

25.42%

2017

$-12.96M

44.43%

2016

$-8.97M

-2.87%

2015

$-9.24M

-43.98%

2014

$-16.49M

-47.21%

2013

$-31.24M

36.42%

2012

$-22.90M

214.42%

2011

$-7.28M

-76.03%

2010

$-30.39M

6.40%

2009

$-28.56M

-22.56%

2008

$-36.88M

3.01%

2007

$-35.80M

56.49%

2006

$-22.88M

0.00%

2005

0.00

0.00%

2004

0.00

-100.00%

2003

$-26.59M

-25.80%

2002

$-35.83M

0.00%

2001

0.00

0.00%

2000

0.00

0.00%

企業	利益	利益の差	国
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-89,641.67%	US
Argenx SE ARGX.US	$1.95B	-33,212.38%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$3.01B	-51,122.19%	BE

企業

利益

利益の差

国